Comparative Pharmacology
Head-to-head clinical analysis: AMEN versus CYCRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMEN versus CYCRIN.
AMEN vs CYCRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progesterone receptor agonist; induces secretory endometrium, inhibits gonadotropin release, and alters cervical mucus.
Medroxyprogesterone acetate is a progestin that inhibits gonadotropin secretion, suppressing ovulation and inducing a withdrawal bleeding in an estrogen-primed endometrium. It exerts its effects via binding to progesterone receptors, leading to endometrial transformation and inhibition of endometrial proliferation.
Medroxyprogesterone acetate (AMEN): 5-10 mg orally once daily for 5-10 days, starting on day 16 or 21 of menstrual cycle; also 150 mg IM every 3 months for contraception.
2.5 mg to 10 mg orally once daily for 5 to 10 days per cycle.
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours. In severe hepatic impairment, half-life may be prolonged up to 12 hours.
Terminal elimination half-life ranges from 12 to 24 hours, supporting once-daily dosing for continuous hormone replacement.
Primarily hepatic metabolism to inactive metabolites, with <1% excreted unchanged in urine. Fecal elimination of metabolites accounts for ~30%.
Primarily renal (50-60% as sulfate and glucuronide conjugates), with approximately 30% fecal elimination.
Category C
Category C
Progestin
Progestin